Robert Ghenchev

Direktor/Vorstandsmitglied bei EXSCIENTIA PLC

43 Jahre

Health Technology

Finance

Technology Services

Profil

Robert Ghenchev is currently Director at Mission Bio, Inc., Exscientia AI Ltd., Exscientia Ltd., Mightyowl, Inc., and Quanta Dialysis Technologies LLC.
Mr. Ghenchev is also Head-Growth Equity at Novo Holdings Equity US, Inc. since 2025.
Former roles include Director at Tempus AI, Inc., Non-Executive Director at Oxford Biomedica Plc from 2019 to 2025, Senior Vice President at Moelis & Company UK LLP from 2010 to 2018, and Managing Partner at Novo Growth from 2018 to 2025.
Education includes a graduate degree from the University of Oxford in 2007 and an undergraduate degree from McGill University in 2006.

Aktive Positionen von Robert Ghenchev

Unternehmen	Position	Beginn
EXSCIENTIA PLC	Direktor/Vorstandsmitglied	01.05.2020
Exscientia AI Ltd. Exscientia AI Ltd. Pharmaceuticals: GenericHealth Technology Provides AI and machine learning techniques based drug discovery services	Direktor/Vorstandsmitglied	01.05.2020
Mission Bio, Inc. Mission Bio, Inc. BiotechnologyHealth Technology Develops single-cell multi-omics platform integrating genotype and phenotype for cancer research and biomarker development	Direktor/Vorstandsmitglied	-
Mightyowl, Inc. Mightyowl, Inc. Internet Software/ServicesTechnology Services Operates as an online educational platform	Direktor/Vorstandsmitglied	-
Novo Holdings Equity Us, Inc. Novo Holdings Equity Us, Inc. Financial ConglomeratesFinance Operates as holding company that provides investment services for life science companies	Corporate Officer/Principal	21.03.2025
Quanta Dialysis Technologies, Inc. Quanta Dialysis Technologies, Inc. Medical SpecialtiesHealth Technology Quanta Dialysis Technologies, Inc. is an American medical technology company focused on transforming kidney care through its dialysis system. The company is located in the US. The platform supports all major hemodialysis modalities, including intermittent hemodialysis, sustained low efficiency dialysis, continuous renal replacement therapy, and home hemodialysis, delivered from a single, compact, portable device without the need for dialysate bags. The system uses disposable cartridge-based dialysate technology that eliminates daily rinses and harsh chemical disinfections, requiring only a once-weekly hot rinse, and offers flexible prescription options with easy training and minimal maintenance. It is designed for use in clinics, ICUs, post-acute care, and home settings, and features a lightweight, space-saving design with an intuitive touchscreen interface. The Quanta cart accessory enhances mobility and modularity for bedside treatments and is compatible with portable reverse osmosis units. The company also provides a digital health platform, CareLinq, for real-time machine connectivity, operational excellence, fleet management, and staff e-learning. Quanta holds worldwide patents and registered trademarks protecting its technology and branding, and its technology is supported by published clinical research and validated through clinical trials.	Direktor/Vorstandsmitglied	-

Alle aktiven Positionen von Robert Ghenchev

Ehemalige bekannte Positionen von Robert Ghenchev

Unternehmen	Position	Ende
Novo Growth Novo Growth Investment ManagersFinance Novo Growth invests in companies located across the globe. The firm focuses on companies operating in the fields of life science, technology, industrial biotechnology, complex manufacturing and supply chain sectors and industries. It participates in growth transactions with an investment size of USD 30 - 100 million.	Private Equity Investor	01.11.2025
OXFORD BIOMEDICA PLC	Direktor/Vorstandsmitglied	20.10.2025
Moelis & Co. (UK) LLP Moelis & Co. (UK) LLP Investment Banks/BrokersFinance Provides brokerage services	Corporate Officer/Principal	01.01.2018
░░░░░░ ░░░ ░░░░	░░░░░░░░░░░░░░░░░░░░░░░░░░	-

Sehen Sie sich die Erfahrung von Robert Ghenchev im Detail an

Ausbildung von Robert Ghenchev

Erfahrungen
Besetzte Positionen

Aktive

Inaktive

Börsennotierte Unternehmen

Private Unternehmen

Sehen Sie sich die Erfahrung von Robert Ghenchev im Detail an

Beziehungen

Beziehungen ersten Grades

Unternehmen ersten Grades

Herr

Frau

Aufsichtsräte

Führungskräfte

Sehen Sie sich das persönliche Netzwerk an

Unternehmensverbindungen

Private Unternehmen	12
Oxford Biomedica Plc Oxford Biomedica Plc BiotechnologyHealth Technology Operates as a contract development and manufacturing organization which provides viral vectors to pharmaceutical and biotechnology clients in cell and gene therapy fields	Health Technology
University of Oxford University of Oxford Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
McGill University McGill University Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
Moelis & Co. (UK) LLP Moelis & Co. (UK) LLP Investment Banks/BrokersFinance Provides brokerage services	Finance
Tempus AI, Inc. Tempus AI, Inc. Packaged SoftwareTechnology Services Develops AI platform for clinical and molecular data testing	Technology Services
Mission Bio, Inc. Mission Bio, Inc. BiotechnologyHealth Technology Develops single-cell multi-omics platform integrating genotype and phenotype for cancer research and biomarker development	Health Technology
Exscientia AI Ltd. Exscientia AI Ltd. Pharmaceuticals: GenericHealth Technology Provides AI and machine learning techniques based drug discovery services	Health Technology
Novo Growth Novo Growth Investment ManagersFinance Novo Growth invests in companies located across the globe. The firm focuses on companies operating in the fields of life science, technology, industrial biotechnology, complex manufacturing and supply chain sectors and industries. It participates in growth transactions with an investment size of USD 30 - 100 million.	Finance
Exscientia Plc Exscientia Plc Packaged SoftwareTechnology Services Function as an investment holding company whose subsidiaries provides artificial intelligence and machine learning services	Technology Services
Mightyowl, Inc. Mightyowl, Inc. Internet Software/ServicesTechnology Services Operates as an online educational platform	Technology Services
Novo Holdings Equity Us, Inc. Novo Holdings Equity Us, Inc. Financial ConglomeratesFinance Operates as holding company that provides investment services for life science companies	Finance
Quanta Dialysis Technologies, Inc. Quanta Dialysis Technologies, Inc. Medical SpecialtiesHealth Technology Quanta Dialysis Technologies, Inc. is an American medical technology company focused on transforming kidney care through its dialysis system. The company is located in the US. The platform supports all major hemodialysis modalities, including intermittent hemodialysis, sustained low efficiency dialysis, continuous renal replacement therapy, and home hemodialysis, delivered from a single, compact, portable device without the need for dialysate bags. The system uses disposable cartridge-based dialysate technology that eliminates daily rinses and harsh chemical disinfections, requiring only a once-weekly hot rinse, and offers flexible prescription options with easy training and minimal maintenance. It is designed for use in clinics, ICUs, post-acute care, and home settings, and features a lightweight, space-saving design with an intuitive touchscreen interface. The Quanta cart accessory enhances mobility and modularity for bedside treatments and is compatible with portable reverse osmosis units. The company also provides a digital health platform, CareLinq, for real-time machine connectivity, operational excellence, fleet management, and staff e-learning. Quanta holds worldwide patents and registered trademarks protecting its technology and branding, and its technology is supported by published clinical research and validated through clinical trials.	Health Technology